title: First report on Ambisome-associated allergic reaction in two Sudanese leishmaniasis patients.
abstract: Post kala-azar dermal leishmaniasis (PKDL) and mucosal leishmaniasis (ML) are serious clinical forms of leishmaniasis caused by Leishmania donovani parasites in Sudan. Although pentavalent antimonys are used as the first line of treatment of all clinical forms of leishmaniasis, persistent PKDL and ML patients are treated with liposomal amphotericin B (Ambisome) as a second-line drug. In this work, we report the development of allergic reactions by a PKDL and a ML Sudanese patient to Ambisome. The findings warrant future close supervision of patients to be treated with the drug.
authors: Institute of Endemic Diseases, University of Khartoum, Sudan. mmukhtar@tropmedicine.org
authors: Maowia
authors: M
authors: Mukhtar
authors: Mona
authors: M
authors: Aboud
authors: Musa
authors: M
authors: Kheir
authors: Sahar
authors: S
authors: Bakhiet
authors: Nazik
authors: N
authors: Abdullah
authors: Ahmed
authors: A
authors: Ali
authors: Nadia
authors: N
authors: Hassan
authors: Elwaleed
authors: E
authors: Elamin
authors: Atif
authors: A
authors: Elagib
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006967:Hypersensitivity / Q000209:etiology*; D007896:Leishmaniasis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013397:Sudan
chemical_list: C068538:liposomal amphotericin B; D000666:Amphotericin B